abstract |
The present invention is a CCR2/5 double antagonist such as N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1, 5-a][1,3,5]triazine-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide; Monoclonal antibodies such as nivolumab; And/or a method of treating cancer in a subject by a combination comprising chemotherapy. |